Ceryvyn Therapeutics Limited (CKDXF)

OTC Healthcare Biotechnology

Ceryvyn Therapeutics Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Melbourne, VIC, AU. The stock last traded at $0.01, up 0.00% on the session, giving a market capitalisation of $13.7M. Its beta of 1.50 implies it has historically moved more than the broad market.

Ceryvyn Therapeutics Ltd is a clinical-stage biopharmaceutical company developing therapies for the rare lung disease lymphangioleiomyomatosis (LAM). Its lead program, CYV-101, is a fusion protein designed to neutralize VEGF-C and VEGF-D, key signaling proteins involved in the disease. The company was formerly known as Opthea Limited.

Ceryvyn Therapeutics Limited is most often compared with the following Healthcare names: